iiinova — where your digital self keeps evolving

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17h

🩺 The evolving role of SBRT in metastatic kidney cancer At the 2nd Florence International Consensus, Prof. Andrew Tang highlights how stereotactic body radiotherapy (SBRT) is becoming an increasingly important part of metastatic renal cell carcinoma (RCC) management. #FlorenceConsensus26

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2026

🗞️ OncoAlert Newsletter | Oct 9–15 REGISTER here 👉 buff.ly/N5gYtAc 🕯️ Remembering Dr. Rachna Shroff: “If you can’t find the sunshine, be the sunshine.” 🚨 FDA approves adjuvant atezolizumab + chemo for Stage III dMMR colon cancer (ATOMIC: recurrence/death ↓50%) 📚 + NRG-BR002, KEYNOTE-966, LAURA

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 14/10/2026

🎥 New GUARD Educational Capsule Dr. Joaquin Mateo of @VHIO in Barcelona 🇪🇸 breaks down TALAPRO-3, Presented at ASCO 2026 and published on the NEJM TALAPRO-3 is the first phase 3 trial of a PARP inhibitor plus ARPI in HRR-altered metastatic hormone-sensitive (APMS) prostate cancer.

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 12/10/2026

FDA NEWS🇺🇸 | Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR #ColonCancer(adults & peds ≥2 yrs). Subcutaneous Tecentriq Hybreza also approved (≥12 yrs, ≥40 kg). Approval based on ATOMIC www.fda.gov/drugs/resour...

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 12/10/2026

🧬 Are we entering a new era of precision breast cancer care—or are treatment complexity, biomarker uncertainty, and unequal access limiting its promise? Advances in Systemic Treatment of Breast Cancer (Review) www.nejm.org/doi/full/10....

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

Exploring New Treatment Strategies and Future Advances in Oncology #FlorenceConsensus26 🇮🇹 Coverage by @OncoAlert 🚨 In "Tumor Evolution and Therapeutic Sequencing in HR+ HER2- Breast Cancer," Barbara Pistilli (Gustave Roussy) contrasts clinical and biological definitions of endocrine resistance

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

Exploring New Treatment Strategies and Future Advances in Oncology #FlorenceOncology26 🇮🇹 Coverage by @OncoAlert 🚨 "What Have We Learned from UK Breast Radiotherapy Trials and What's Next?", Charlotte Coles (University of Cambridge) traces three decades of UK trials. START, FAST & FAST-Forward

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

Exploring New Treatment Strategies and Future Advances in Oncology #FlorenceOnco26 Coverage by @OncoAlert 🚨 In "From Patients to Partners: The Power of Advocacy in Oncology," patient advocate Hilary Stobart (Independent Cancer Patients' Voice) distinguishes patient involvement, engagement

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

A Great start to #FlorenceOncology26 🇮🇹 with WARMING UP: Exploring New Treatment Strategies and future Advances in Oncology!! Hope you are here to join us in Florence Italy to experience firsthand some great presentations and discussions in #BreastCancer , #ProstateCancer , #HeanandNeckCancer & More

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

After IO, the road in #RCC gets murky 🌫️ So our good friends the UROMIGOS (Dr. Brian Rini & Dr. Tom Powles) asked global experts to score each option, from 0 (avoid) to 3 (SOC). Where's the consensus, and where's the split? 🔥 Dr. Laurence Albiges walks us through it 👇 #KidneyCancer #GUOnc

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2026

This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc 🔦 MATTERHORN: perioperative durvalumab + FLOT improves overall survival in resectable gastric cancer, a new standard of care ✅ FDA approval based on HER2CLIMB

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 07/10/2026

FDA NEWS🇺🇸 HER2CLIMB-05 Update in #BreastCancer On October 7, 2026, the FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy.

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 07/10/2026

🧬 Could immune biology finally tell us which patients with extensive-stage SCLC are most likely to benefit from TIGIT-based therapy? www.ovid.com/journals/jto... SKYSCRAPER-02C🫁 Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage #SCLC

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2026

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow** 📅 November 11–13, 2026 📍 New York, NY 🇺🇸 💻 Hybrid Meeting — In Person + Online 🎟️ FREE REGISTRATION with code: ONCOALERT 👉 buff.ly/b5A7hsf

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2026

📣 Early Bird Registration for #IKCSNA26 Now Open Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America www.kidneycancer.org/event/2026-i...

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2026

The OncoAlert #ESMO26 PULSE is ready 🇪🇸 As Madrid gets closer, your OncoAlert Network has gathered the faculty who will report live from ESMO and keep you up to date on the science out of Spain. In the room or following from home, we've got you covered. ✅ Less noise ✅ No nonsense ✅ Just science

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2026

Is perioperative immunotherapy finally changing the standard of care in resectable gastric cancer? 🧬 www.thelancet.com/journals/lan... Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma MATTERHORN

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2026

Dear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments (endorsed by ESTRO) ) REGISTER HERE 👉 buff.ly/I8wKRpo

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 05/10/2026

Does adding immunotherapy to SBRT ☢️ actually improve outcomes in early-stage, medically inoperable NSCLC🫁 —or simply add toxicity? www.thelancet.com/journals/lan... Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early NSCLC

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 03/10/2026

Could biomarkers🎯 help us better identify which patients with advanced RCC are most likely to benefit from immunotherapy? www.annalsofoncology.org/article/S092... KEYNOTE427 Results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab 🧪 mono in advanced RCC

120 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 02/10/2026

This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc This week's must-reads: 🔸 Spotlight: Giredestrant + everolimus in ER+/HER2− ABC, PFS HR 0.38 in ESR1m (NEJM) 🔸 FDA: belzutifan + lenvatinib approved in ccRCC;

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 01/10/2026

Giredestrant plus Everolimus in Advanced Breast Cancer Could targeting both ER and PI3K–AKT–mTOR pathways help overcome endocrine resistance? 👇 www.nejm.org/doi/full/10....

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/09/2026

Why do some TNBC tumors respond to immunotherapy🧪 while others rapidly develop resistance? www.cell.com/cell-reports... A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics

001 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 29/09/2026

🚨 Join us at the 2026 International Symposium of Gastrointestinal Oncology (#ISGIO2026), October 2–3, 2026! 🆓 FREE registration with code: ONCOALERT 👉 Register: www.gotoper.com/courses/meet... This multidisciplinary program covers the latest advances in GI cancer research and biomarkers

020 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 29/09/2026

Dear GU Colleagues at #ASTRO26 ! Join us at the first LPCCC – Localised Prostate Cancer Consensus Conference, where challenging and unresolved questions in Prostate Cancerwill be discussed, debated and brought into focus. #LPCCC27 JUST NOW CALL FOR ABSTRACTS ARE OPEN apccc.org/call-for-abs...

001 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 SIX-YEAR OVERALL SURVIVAL OF NIVOLUMAB FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY IN EARLY-STAGE NON-SMALL CELL LUNG CANCER: RANDOMIZED I-SABR TRIAL Presented by Dr. Joe Chang🇺🇸

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 LBA 03 - SWOG S1827/MAVERICK: A RANDOMIZED PHASE III TRIAL OF BRAIN MRI SURVEILLANCE WITH AND WITHOUT PROPHYLACTIC CRANIAL IRRADIATION (PCI) FOR SMALL-CELL LUNG CANCER (SCLC) Presented by Dr. Paul Brown 🇺🇸

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 STEREOTACTIC BODY RADIATION THERAPY (SBRT) AND COMPREHENSIVE METASTASIS-DIRECTED THERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/09/2026

🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca Submission is supported by VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and OS

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/09/2026

What if a missed cancer diagnosis could cost you 8 years of life? 🚨 On this #WeekinOncology #Melanoma by OncoAlert🚨, our #OncoAlertAF colleagues Dr. Mario Balsa 🇪🇸 discusses an article out on Nature communications www.nature.com/articles/s41...

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

FDA 🇺🇸 News: LITESPARK-011 Update in #kidneyCancer Source: FDA www.fda.gov/drugs/resour... On September 24, 2026, the FDA🇺🇸 approved belzutifan plus lenvatinib for adults with advanced renal cell carcinoma containing a clear cell component after PD-1/PD-L1 inhibitor treatment. In the LITESPARK-011

001 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 buff.ly/b5A7hsf HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

Join us at 2026 International Symposium of Gastrointestinal Oncology on October 2–3, 26 🚨 FREE🆓 REGISTRATION with Code: ONCOALERT REGISTER 👉 buff.ly/Rld9coM

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

Can a blood🩸 test detect cancer earlier—but still fail to demonstrate clinical utility? www.nejm.org/doi/full/10.... Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

FDA News: REFOCUS Update in #Cholangiocarcinoma On September 23, 2026, the FDA🇺🇸 approved lirafugratinib for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2🧬 fusions or rearrangements. www.fda.gov/drugs/resour...

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

What does 6 years of follow-up tell us about 1 year of adjuvant olaparib? The OlympiA trial continues to show meaningful improvements in disease-free and overall survival in high-risk, HER2-negative early #BreastCancer

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

This week’s OncoAlert 🚨 Newsletter is OUT ^ packed with the latest in Oncology Don’t miss the latest updates—register to get it 👉 buff.ly/N5gYtAc The new ABC8 guidelines update advanced breast cancer care worldwide. An AI tool helps predict who benefits from immunotherapy in lung cancer.

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/09/2026

The OncoAlert HORIZONS Series: Breast Cancer What happens when Watch & Wait fails? How Mechanism based therapies are rewriting Cancer Care WATCH THE ENTIRE VIDEO HERE👉 youtu.be/Efk2mf0RnNA?...

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

📣 Early Bird Registration for #IKCSNA26 Now Open Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America www.kidneycancer.org/event/2026-i...

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 buff.ly/N5gYtAc → Tambotatug pelitecan nearly doubled response rates over topotecan in relapsed small-cell lung cancer — 59.1% vs 9.7% — with fewer grade ≥3 events (NEJM)

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/09/2026

Join us at 2026 International Symposium of Gastrointestinal Oncology on October 2–3, 26 🚨 FREE🆓 REGISTRATION with Code: ONCOALERT REGISTER 👉 buff.ly/Rld9coM This multidisciplinary program focuses on the latest advances in GI cancer research, biomarkers, and personalized treatment.

010 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 buff.ly/3G9pRP6 HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY Two | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 How do we break through the IO + TKI plateau in kidney cancer? Dr. Guillermo de Velasco 🇪🇸 from Hospital Universitario 12 de Octubre, Madrid, maps four emerging strategies in advanced #RCC — HIF-2α inhibition, T-cell engagers/CAR-T

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY TWO | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Does every patient with HRR-mutated prostate cancer need a PARP inhibitor plus ARPI — and does which PARPi you choose matter? Dr. Charles Ryan 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, delivers a keynote lecture on PARP inhibitor mgt.

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 What comes after enfortumab vedotin in urothelial cancer? Dr. Jonathan E. Rosenberg 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, looks ahead to the next wave of ADCs and the biomarkers that will guide their use in #UrothelialCarcinoma 🔬

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 With no randomised evidence in second line, how should clinicians sequence therapy after EV+pembrolizumab in advanced bladder cancer? Dr. Urbano Anido 🇪🇸 from Complexo Hospitalario Universitario de Santiago

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY 3 | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Can we safely de-escalate perioperative therapy in muscle-invasive bladder cancer? Dr. Andrea Necchi 🇮🇹 reviews the evolving standard of care for #MIBC — from sandwich (neoadjuvant + adjuvant) immunotherapy to next-generation bladder-sparing strategies

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Is it finally time for ctDNA to guide treatment decisions in bladder cancer? Dr. Sara Coca Membribes 🇬🇧 from Barts Cancer Institute, London, walks through the full biomarker landscape shaping therapy in #BladderCancer

000 0

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

Are we truly personalizing treatment for premenopausal women with HR+/HER2− early breast cancer—or still applying evidence largely built around postmenopausal populations? 🎗️ www.sciencedirect.com/science/arti...

000 0